Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

The Global Anti-Addiction Market, 2008-2023

Published by: Visiongain

Published: Nov. 5, 2008 - 138 Pages


Table of Contents


1 Executive Summary

2 Introduction: Worldwide Prevalence and Treatment of Addiction

2.1 The Physiology and Psychology of Addiction

2.1.1 Definition of Addiction

2.1.2 Addiction is Caused by Physical Dependence

2.1.3 Psychological Dependence

2.2 Prevalence of Addiction

2.3 Addiction Therapy

2.3.1 Behavioural Therapy

2.3.2 Addiction Treatment with Drugs

2.3.3 Off-Label Drug Prescribing for Addiction Therapy

2.4 Smoking Cessation Products

2.4.1 Nicotine Replacement Therapy (NRT)

2.4.2 Nicotine Replacement Therapy Products (Johnson & Johnson)

2.4.3 Nicotine Replacement Therapy Products (GSK)

2.4.4 Nicotine Replacement Therapy Products (Novartis)

2.4.5 Chantix/Champix (Pfizer)

2.4.6 Zyban (GSK/Biovail)

2.5 Obesity Drugs

2.5.1 Xenical (Roche)

2.5.2 Reductil/Meridia (Abbott Laboratories)

2.5.3 Alli (GSK)

2.5.4 Acomplia (Sanofi-Aventis)

2.5.5 Other Obesity Drugs

2.6 Drugs Used In Opioid Dependence

2.6.1 Suboxone/Subutex (Reckitt Benckiser/ Schering-Plough)

2.6.2 Methadone

2.6.3 Naltrexone

2.6.4 Other Drugs Used in Opioid Addiction Treatment

2.7 Alcohol Dependency Drugs

2.7.1 Campral/Aotal (Merck KGaA/Forest)

2.7.2 Antabuse (Barr)

2.7.3 Naltrexone

2.7.4 Vivitrol (Alkermes/Cephalon/Johnson & Johnson)

2.7.5 Revia (Barr/Bristol-Myers Squibb)


3 The Global Addiction Market

3.1 The Addiction Market in 2007

3.1.1 Leading Addiction Therapy Areas, 2007

3.1.2 Leading Addiction Brands, 2007

3.1.3 Leading Manufacturers of Addiction Drugs, 2007

3.2 Global Addiction Market Forecasts, 2008-2023

3.2.1 Addiction Market Forecast, 2008-2023

3.2.2 Addiction Therapy Area Sales Forecast, 2008-2023


4 The Global Smoking Cessation Market

4.1 The Smoking Cessation Market in 2007

4.1.1 Leading Smoking Cessation Product Types, 2007

4.1.2 Leading Manufacturers of Smoking Cessation Products, 2007

4.2 Smoking Cessation Market Forecasts, 2008-2023

4.2.1 Global Smoking Cessation Market Forecast, 2008-2023

4.2.2 Smoking Cessation Product Type Sales Forecast, 2008-2023

4.2.3 Chantix/Champix Sales Forecast, 2008-2023


5 The Global Obesity Market

5.1 The Obesity Market in 2007

5.1.1 Leading Obesity Brands, 2007

5.1.2 Leading Manufacturers of Obesity Drugs, 2007

5.2 Obesity Market Forecasts, 2008-2023

5.2.1 Global Obesity Market Forecast, 2008-2023

5.2.2 Xenical Sales Forecast, 2008-2023

5.2.3 Reductil/Meridia Sales Forecast 2008-2023

5.2.4 Alli Sales Forecast, 2008-2023

5.2.5 Acomplia Sales Forecast, 2008-2023


6 The Global Drug Addiction Market

6.1 The Drug Addiction Market in 2007

6.1.1 Leading Drug Addiction Product Types, 2007

6.1.2 Leading Manufacturers of Drug Addiction Products, 2007

6.2 Drug Addiction Market Forecasts, 2008-2023

6.2.1 Global Drug Addiction Market Forecast, 2008-2023

6.2.2 Drug Addiction Product Type Sales Forecast, 2008-2023

6.2.3 Suboxone/Subutex Sales Forecast, 2008-2023


7 The Global Alcohol Dependency Market

7.1 The Alcohol Dependency Market in 2007

7.1.1 Leading Alcohol Dependency Drug Types, 2007

7.1.2 Leading Manufacturers of Alcohol Dependency Drugs, 2007

7.2 Alcohol Dependency Market Forecasts, 2008-2023

7.2.1 Global Alcohol Dependency Market Forecast, 2008-2023

7.2.2 Alcohol Dependency Drug Type Sales Forecast, 2008-2023

7.2.3 Campral/Aotal Forecast, 2008-2023

7.2.4 Vivitrol Sales Forecast, 2008-2023


8 Leading Addiction Country Markets

8.1 Top Twelve Addiction Country Markets, 2007

8.2 Addiction Market Country Forecasts, 2008-2023

8.3 The US Addiction Market

8.3.1 Prevalence of Addiction in the US

8.3.2 Smoking Cessation Dominated the US Addiction Market in 2007

8.3.3 Forecast for the US Addiction Market, 2008-2023

8.4 The UK Addiction Market

8.4.1 Prevalence of Addiction in the UK

8.4.2 There is Greater Reimbursement of Addiction Drugs in the UK Market

8.4.3 Forecast for the UK Addiction Market, 2008-2023

8.5 The French Addiction Market

8.5.1 Prevalence of Addiction in France

8.5.2 France has High Revenues in the Drug and Alcohol Addiction Markets

8.5.3 Forecast for the French Addiction Market, 2008-2023


9 SWOT Analysis of the Addiction Market

9.1 Analysis of the Market

9.2 Strengths of the Addiction Industry

9.2.1 Development of Addiction Vaccines and Novel Drug Formulations

9.2.2 Expansion into New Therapeutic Areas

9.3 Weaknesses of the Addiction Therapy Industry

9.3.1 Currently Marketed Addiction Therapies Lack Efficacy

9.3.2 Poor Patient Compliance

9.4 Opportunities in the Addiction Market

9.4.1 Addiction is Prevalent Worldwide and Increasing

9.4.2 Prevalence of Tobacco Use Worldwide and in Major Country Markets

9.4.3 Prevalence of Obesity Worldwide and in Major Country Markets

9.4.4 Prevalence of Drug Use Worldwide and in Major Country Markets

9.4.5 Alcohol Consumption and Dependence Worldwide and in Major

Country Markets

9.4.6 There is Considerable Under-Treatment of Patients

9.4.7 The Cost of Addiction is High

9.4.8 Awareness of the Costs of Addiction is Increasing

9.4.9 Smoking Legislation is Spreading

9.5 Threats to the Addiction Market

9.5.1 Reimbursement is the Key to Success in the Addiction Market

9.5.2 Concern over Side-Effects of Addiction Drugs

9.5.3 Behavioural Therapy is Often Preferred to Treatment with Drugs

9.5.4 Social Stigma and Lack of Education and Resources


10 The Addiction Therapy Pipeline

10.1 Some Areas of the Addiction Pipeline are Stronger than Others

10.2 The Smoking Cessation Product Pipeline

10.2.1 Addiction Vaccines Will Target Nicotine Dependence

10.2.2 Surinabant (Sanofi-Aventis)

10.2.3 EVT 302 (Evotec)

10.2.4 NicVAX (Nabi Biopharmaceuticals)

10.2.5 NIC002 (Cytos Biotechnology/Novartis)

10.2.6 TA-NIC (Celtic Pharma)

10.2.7 Niccine (Independent Pharmaceutica)

10.3 The Obesity Drug Pipeline

10.3.1 The Obesity Pipeline has had a High Failure Rate

10.3.2 Contrave (Orexigen)

10.3.3 CP-945598/Otenabant (Pfizer)

10.3.4 Lorcaserin (Arena)

10.3.5 Qnexa (Vivant)

10.3.6 ATL-962/Cetilistat (Alizyme/Takeda)

10.3.7 Pramlintide/Metreleptin (Amylin)

10.3.8 Histalean (OBEcure)

10.3.9 Empatic (Orexigen)

10.3.10 Liraglutide (Novo Nordisk)

10.4 The Drug Addiction Therapy Pipeline

10.4.1 Cocaine Treatment is the Most Promising Drug Addiction Pipeline Area

10.4.2 Vivitrol (Alkermes)

10.4.3 Probuphine (Titan)

10.4.4 TA-CD (Celtic Pharma)

10.4.5 SYN-117 (Synosia Therapeutics/Roche)

10.4.6 Lobeline (Yaupon Therapeutics)

10.4.7 Naltrexone Implant (Indevus)

10.4.8 Tetrodin (WEX Pharmaceuticals)

10.4.9 XY2401 (Xytis/National Institute on Drug Abuse/Rottapharm)

10.5 The Alcohol Dependency Therapy Pipeline

10.5.1 The Alcohol Dependency Pipeline Has Plenty of Room for Novel Products

10.5.2 Nalmefene (Biotie Therapies /Lundbeck/Somaxon): A New Drug for Dependency Disorders

10.5.3 Naltrexone Depot (Elbion NV)

10.5.4 ALKS 29 (Alkermes)

10.6 The Pipeline for Other Addiction Therapies


11 Expert Opinion from Key Opinion-Leaders in the Addiction Industry

11.1 Dr Raafat Fahim, President and Chief Executive Officer, Nabi Biopharmaceuticals

11.1.1 Vaccines in the Pipeline for Nicotine Addiction

11.1.2 NicVAX

11.1.3 Other Nicotine Vaccines

11.2 Industry Representative from the Addiction Therapy Sector

11.2.1 Type of Addictions with Greatest Market Growth Potential

11.2.2 Key Unmet Needs For Alcohol Dependent Patients

11.2.3 Key Advantages of Nalmefene

11.2.4 The Future of the Alcohol Dependency Market


12 Conclusions

12.1 The Addiction Market in 2007

12.2 Opportunity for Growth in the Addiction Market

12.3 Visiongain's Forecast for the Addiction Market, 2008-2023


List of Tables

Table 2.1 Global Prevalence of Addiction and Drug Use

Table 2.2 Key Drugs Prescribed Off-Label for Addiction Therapy

Table 2.3 Major Johnson & Johnson Nicotine Replacement Therapy Brands

Table 2.4 Major GSK Nicotine Replacement Therapy Brands

Table 2.5 Major Novartis Nicotine Replacement Therapy Brands

Table 3.1 Leading Addiction Therapy Areas, 2007

Table 3.2 Leading Addiction Brands, 2007

Table 3.3 Leading Manufacturers of Addiction Drugs, 2007

Table 3.4 Global Addiction Market Forecast, 2008-2013

Table 3.5 Global Addiction Market Forecast, 2014-2023

Table 3.6 Addiction Therapy Area Sales Forecast, 2008-2013

Table 3.7 Addiction Therapy Area Sales Forecast, 2014-2023

Table 4.1 Leading Smoking Cessation Product Types, 2007

Table 4.2 Leading Manufacturers of Smoking Cessation Products, 2007

Table 4.3 Global Smoking Cessation Market Forecast, 2008-2013

Table 4.4 Global Smoking Cessation Market Forecast, 2014-2023

Table 4.5 Smoking Cessation Product Type Sales Forecast, 2008-2013

Table 4.6 Smoking Cessation Product Type Sales Forecast, 2014-2023

Table 5.1 Leading Obesity Brands, 2007

Table 5.2 Leading Manufacturers of Obesity Drugs, 2007

Table 5.3 Global Obesity Market Forecast, 2008-2013

Table 5.4 Global Obesity Market Forecast, 2014-2023

Table 5.5 Obesity Brands Sales Forecasts, 2008-2013

Table 5.6 Obesity Brands Sales Forecasts, 2014-2023

Table 6.1 Leading Drug Addiction Product Types, 2007

Table 6.2 Leading Manufacturers of Drug Addiction Products, 2007

Table 6.3 Global Drug Addiction Market Forecast, 2008-2013

Table 6.4 Global Drug Addiction Market Forecast, 2014-2023

Table 6.5 Drug Addiction Product Type Sales Forecast, 2008-2013

Table 6.6 Drug Addiction Product Type Sales Forecast, 2014-2023

Table 6.7 Suboxone/Subutex Sales Forecast, 2008-2013

Table 6.8 Suboxone/Subutex Sales Forecast, 2014-2023

Table 7.1 Leading Alcohol Dependency Drug Types, 2007

Table 7.2 Leading Manufacturers of Alcohol Dependency Drugs, 2007

Table 7.3 Global Alcohol Dependency Market Forecast, 2008-2013

Table 7.4 Global Alcohol Dependency Market Forecast, 2014-2023

Table 7.5 Alcohol Dependency Drug Type Sales Forecast, 2008-2013

Table 7.6 Alcohol Dependency Drug Type Sales Forecast, 2014-2023

Table 7.7 Campral/Aotal and Vivitrol Sales Forecast, 2008-2013

Table 7.8 Campral/Aotal and Vivitrol Sales Forecast, 2014-2023

Table 8.1 Top Twelve Addiction Country Markets, 2007

Table 8.2 Addiction Market Country Forecasts, 2008-2013

Table 8.3 Addiction Market Country Forecasts, 2014-2023

Table 8.4 Prevalence of Addiction and Drug Use in the US

Table 8.5 The US Addiction Market, 2007

Table 8.6 Prevalence of Addiction and Drug Use in the UK

Table 8.7 The UK Addiction Market, 2007

Table 8.8 Prevalence of Addiction and Drug Use in France

Table 8.9 The French Addiction Market, 2007

Table 9.1 SWOT Chart for Addiction Market

Table 9.2 Prevalence of Tobacco Use Worldwide and in Major Country Markets

Table 9.3 Prevalence of Obesity Worldwide and in Major Country Markets

Table 9.4 Worldwide Drug Use, 2006/07

Table 9.5 Prevalence of Opioid Drug Use Worldwide and in Major Country Markets

Table 9.6 Prevalence of Cocaine Use Worldwide and in Major Country

Table 9.7 Alcohol Consumption & Dependence Worldwide & in Major Country Markets

Table 10.1 Key Smoking Cessation Pipeline Products

Table 10.2 Key Obesity Pipeline Drugs

Table 10.3 Key Drug Addiction Pipeline Therapies

Table 10.4 Key Alcohol Dependency Pipeline Drugs


List of Figures

Figure 3.1 Leading Addiction Therapy Areas, 2007

Figure 3.2 Leading Addiction Brands, 2007

Figure 3.3 Leading Manufacturers of Addiction Drugs, 2007

Figure 3.4 Global Addiction Market Forecast, 2008-2023

Figure 3.5 Addiction Therapy Area Sales Forecast, 2008-2023

Figure 3.6 Addiction Therapy Area Sales Forecast and Market Share, 2008-2023

Figure 3.7 Addiction Therapy Area Market Share, 2013

Figure 3.8 Addiction Therapy Area Market Share, 2018

Figure 3.9 Addiction Therapy Area Market Share, 2023

Figure 4.1 Leading Smoking Cessation Product Types, 2007

Figure 4.2 Leading Manufacturers of Smoking Cessation Products, 2007

Figure 4.3 Global Smoking Cessation Market Forecast, 2008-2023

Figure 4.4 Smoking Cessation Product Type Sales Forecast, 2008-2023

Figure 4.5 Smoking Cessation Product Type Sales Forecast & Market Share, 2008-2023

Figure 4.6 Chantix/Champix Sales Forecast, 2008-2023

Figure 5.1 Leading Obesity Brands, 2007

Figure 5.2 Leading Manufacturers of Obesity Drugs, 2007

Figure 5.3 Global Obesity Market Forecast, 2008-2023

Figure 5.4 Xenical Sales Forecast, 2008-2023

Figure 5.5 Reductil/Meridia Sales Forecast, 2008-2023

Figure 5.6 Alli Sales Forecast, 2008-2023

Figure 5.7 Acomplia Sales Forecast, 2008-2023

Figure 6.1 Leading Drug Addiction Product Types, 2007

Figure 6.2 Leading Manufacturers of Drug Addiction Products, 2007

Figure 6.3 Global Drug Addiction Market Forecast, 2008-2023

Figure 6.4 Drug Addiction Product Type Sales Forecast, 2008-2023

Figure 6.5 Drug Addiction Product Type Sales Forecast and Market Share, 2008-2023

Figure 6.6 Suboxone/Subutex Sales Forecast, 2008-2023

Figure 7.1 Leading Alcohol Dependency Drug Types, 2007

Figure 7.2 Leading Manufacturers of Alcohol Dependency Drugs, 2007

Figure 7.3 Global Alcohol Dependency Market Forecast, 2008-2023

Figure 7.4 Alcohol Dependency Drug Type Sales Forecast, 2008-2023

Figure 7.5 Alcohol Dependency Drug Type Sales Forecast and Market Share, 2008-2023

Figure 7.6 Campral/Aotal Sales Forecast, 2008-2023

Figure 7.7 Vivitrol Sales Forecast, 2008-2023

Figure 8.1 Leading Addiction Country Markets, 2007

Figure 8.2 Leading Addiction Country Markets, 2013

Figure 8.3 Leading Addiction Country Markets, 2018

Figure 8.4 Leading Addiction Country Markets, 2023

Figure 8.5 The US Addiction Market, 2007

Figure 8.6 US Addiction Market Sales Forecast, 2008-2023

Figure 8.7 The UK Addiction Market, 2007

Figure 8.8 UK Addiction Market Sales Forecast, 2008-2023

Figure 8.9 The French Addiction Market, 2007

Figure 8.10 French Addiction Market Sales Forecast, 2008-2023

Figure 9.1 Top-Ten Countries for Numbers of Tobacco Users

Figure 9.2 Prevalence of Obesity in Major Country Markets

Figure 9.3 Prevalence of Opioid Drug Use in Major Country Markets

Figure 9.4 Prevalence of Cocaine Use in Major Country Markets

Figure 9.5 Alcohol Consumption and Dependence in Major Country Markets

Abbott Laboratories

Actavis

Alizyme

Alkermes

Amylin

Arena

AstraZeneca

Barr

Biotie Therapies (Finland)

Biovail

Bristol-Myers Squibb

Celtic Pharma

Cephalon

CV Therapeutics

Cytos Biotechnology

Drake University (US)

Eisai

Elbion NV

Eli Lilly

European Medicines Agency (EMEA)

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

Evotec

Food and Drug Administration (FDA)

Forest

GSK

Independent Pharmaceutica

Indevus

Johnson & Johnson

Karolinska Institutet (Sweden)

Lundbeck

Medley (Brazil)

Merck & Co.

Merck KGaA

Nabi Biopharmaceuticals

National Health Service (NHS, UK)

National Institute for Health and Clinical Excellence (NICE, UK)

National Institute on Drug Abuse (NIDA, USA)

National Institutes of Health (NIH, USA)

Novartis

Novo Nordisk

OBEcure

Orexigen

Pfizer

Reckitt Benckiser

Roche

Rottapharm (Italy)

Sanofi-Aventis

Schering-Plough

Solvay

Somaxon

Synosia Therapeutics

Takeda

Titan

Vivant

WEX Pharmaceuticals

World Health Organization (WHO)

Xytis

Yaupon Therapeutics





Abstract

The global addiction market is significantly undervalued. The world’s population has a large unmet need for addiction therapy drugs. Are you ready for the opportunities this presents? The brand new report, The Global Anti-Addiction Market, 2008-2023, provides an in-depth analysis of the current state of the market for addiction therapy drugs, from the present looking forward. It covers the major therapy areas of smoking cessation, obesity, drug addiction and alcohol dependency. In addition, this study forecasts how your market will grow and develop, both quantitatively and qualitatively, during the period 2008-2023.

The Global Anti-Addiction Market, 2008-2023, uses a variety of primary and secondary research methods, including:
  • Exclusive visiongain interviews with key opinion leaders in the addiction industry
  • Examination of a wealth of secondary sources, including company reports, filings, analyst presentations and press releases
  • Use of in-house and commercial sales databases.
Addiction rates are increasing, yet there is a relative lack of widely-efficacious drugs. Also, relatively few patients are treated and patient compliance is low for those who are treated at present. Nevertheless, the growth potential market of this market is significant, both in developed and developing countries. In addition, awareness of the human and healthcare costs associated with addiction is increasing amongst patients, healthcare practitioners and legislators. There is a sense of urgency to combat tobacco addiction, alcoholism and obesity in particular. Consequently, there are marked opportunities for companies marketing and developing anti-addiction drugs. But by how much will the market grow and which therapy areas will be the fastest growing? This report answers those questions and more besides.

Visiongain has applied detailed financial forecasting and analysis of market/industry drivers and restraints, including SWOT analysis. The resulting comprehensive market-based report reveals how leading addiction brands, therapy areas and markets will fare during the period 2008 to 2023. Key features of the addiction drugs of the future and the hurdles they will have to overcome for commercial success are discussed.

Other highlights of The Global Anti-Addiction Market, 2008-2023 report include:
  • Expert opinion from representatives in the anti-addiction drug industry
  • Sales forecasts for the global addiction market and for individual obesity, smoking cessation, drug addiction and alcohol addiction markets, including leading brands, manufacturers and country markets
  • Examination of strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in the anti-addiction drugs market
  • In-depth analysis of the anti-addiction pipeline
  • Geographical breakdown of the anti-addiction drugs market
  • Analysis of the addiction markets in the US, France and the UK.
Why you should buy this report:
  • To receive a comprehensive analysis of the prospects for anti-addiction drugs, including key metrics and predicted revenues, by type of addiction and brand
  • To receive forecasts of addiction drug sales, from 2008-2023, in leading country markets, including China and Mexico
  • To read the views of experts in the addiction industry, regarding current and future trends, opportunities and sales drivers; the report includes full transcripts of interviews
  • The report is packed with graphs, charts, figure and tables of analysis and sales forecasts
  • To determine the forces that influence the market for anti-addiction drugs: drivers, restraints, opportunities and competitive factors
  • To find out where the addiction market is heading - both technologically and commercially from 2008 onwards.
The information contained in this report is not available in any other source and is essential reading for you and your colleagues. By ordering and reading this report you can gain market advantage on your competitors today. When aligned with your in-house findings we are confident you will continue to succeed over the next 15 years.

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options

See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009